Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LYN-014 in Stable Opioid Use Disorder
NCT05251376Phase 1Withdrawn
- Sponsor
- Lyndra Therapeutics
- Start
- Feb 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of LYN-014 in opioid use disorder (OUD), sponsored by Lyndra Therapeutics. Primary endpoints: Safety and Tolerability of LYN-014 at 52 days, Minimum Plasma Concentration (Cmin) of Levomethadone at 52 days and 9 more. Planned start Feb 2022; status: withdrawn.
02
Drugs
LYN-014
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT05251376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05251376.